Philadelphia, PA, United States
Philadelphia, PA, United States

Drexel University is a private research university with three campuses in Philadelphia and one in Sacramento, California. It was founded in 1891 by Anthony J. Drexel, a noted financier and philanthropist. Drexel offers over 70 full-time undergraduate programs and accelerated degrees. At the graduate level, the university offers over 100 masters, doctoral, and professional programs, many available part-time.Drexel is best known for the cooperative education program . Drexel's co-op is regularly ranked as one of the best co-op programs in the United States. Participating students have a variety of opportunities to gain up to 18-months of paid full-time working experience before graduation. The university has a large network of more than 1,600 corporate, governmental, and non-profit partners in 28 states and 25 international locations. The employers include top ranked multinational law firms, banks, corporations, and many Fortune 500 companies, such as Goldman Sachs, Microsoft, and Procter & Gamble.Shanghai Jiao Tong University’s academic ranking of world universities ranks Drexel 401-500 and Times Higher Education World University Rankings placed Drexel among the top 200 universities in the World. In U.S. News & World Report's annual "America's Best Colleges List", the university has been ranked consistently among the "Best National Universities – Top Schools." The 2012 rankings place Drexel third in their list of “Up and Coming National Universities” for "promising and innovative changes in the areas of academics, faculty, and student life." In addition, the National Science Foundation and the 2009 Lombardi Report also ranked Drexel among the top 50 private comprehensive research universities. Drexel University ranks #45 among "Research Universities by Salary Potential" in the United States. Wikipedia.


Time filter

Source Type

The present invention relates generally to compositions and methods for treating diseases and disorders caused by herpes simplex virus type 1, including herpes simplex keratitis, in a subject. In certain embodiments, the compositions of the present invention comprise an ATM inhibitor and an anti-herpetic agent. In other embodiments, the compositions comprise a Chk2 inhibitor and an anti-herpetic agent. In yet other embodiments, the compositions comprise a Chk2 inhibitor and an ATM inhibitor, and optionally an anti-herpetic agent.


Pharmaceutical compositions of the invention comprise substituted aminothiazoles derivatives having a disease-modifying action in the treatment of diseases associated with unregulated cell growth that include hepatocellular carcinoma, and infection with a hepatitis virus.


Patent
Thomas Jefferson University and Drexel University | Date: 2016-08-29

An implantable medical device having a sheath formed of a polymer material, wherein the sheath forms a reservoir attached to or around the implantable medical device, and wherein the reservoir is sealed with a biocompatible pressure responsive coating; wherein the biocompatible coating is stable for at least 7-day post implantation into a body, and can be mechanically ruptured by application of an exterior pressure generating force.


Patent
Drexel University | Date: 2016-12-01

A device and method for determining the presence or absence, or the level of, sPLA2 activity in a fluid sample. The device includes an absorbent matrix that defines a flow path for a fluid sample, a first region of the absorbent matrix for applying a fluid sample, where one of the components selected from a bioactive sPLA2 substrate and a label is dried onto or within the first region of the absorbent matrix, a second region of the absorbent matrix downstream of, and in fluid communication with, the first region for detecting an aggregated reaction product, where the other component not present in the first region is dried onto or within the second region of the absorbent matrix.


One aspect of the invention provides a method of inhibiting, protecting against, or treating UVR-induced skin damage in a mammal at risk of developing UVR-induced skin damage. The method includes the step of topically administering a pharmaceutical or cosmetic composition including an effective amount of a Syk kinase inhibitor to said mammal. The Syk kinase inhibitor inhibits the UVR-induced skin damage in the mammal. Another aspect of the invention provides a method of treating a disease or disorder associated with a change of Syk kinase expression in the skin in a mammal. The method includes the step of topically administering to said skin of said mammal a pharmaceutical or cosmetic composition including a therapeutically effective amount of at least one Syk kinase inhibitor, thereby reducing Syk kinase expression in the skin of the mammal and treating the disease or disorder.


Patent
Drexel University | Date: 2016-10-20

The application relates to the delivery of immunomodulatory molecules, including cytokines, to the situs of tissue scaffolds, and wounds including injuries.


Patent
Drexel University | Date: 2017-01-31

Provided are methods and compositions that can he used to treat subjects having a viral infection by provoking an immune response using newly discovered antigens that are non-naturally occurring variations on viral glycoproteins. For example, provided are viral glycoproteins or a fragments thereof, or, DNA constructs encoding for such viral glycoproteins or fragments thereof, wherein the glycoprotein or fragment comprises a glycosylation sequon that includes a non-templated aspartic acid residue.


Patent
Drexel University | Date: 2017-04-26

A system for measuring structural integrity includes a self-contained rapid modal testing trailer that delivers an impact load to a structure being tested and records data resulting from the impact load, and a data processing software that extracts modal parameters of the structure, such as frequencies and mode shapes. The parameters are used to determine anomalous behavior as well as provide experimental data for finite element model calibration.


The invention includes a mammal-safe method of killing or harming an insect. The method comprises administering to the insect a composition comprising erythritol ((2R,3S)-butane-1,2,3,4-tetraol).


Patent
Drexel University, Baruch S Blumberg Institute and Hoffmann-La Roche | Date: 2017-04-26

The present invention relates to methods and uses for screening anti-hepadnaviral substances, wherein the substances are screened for the capacity to inhibit covalently closed circular (ccc) DNA of a hepadnavirus, like hepatitis B virus. The methods and uses take advantage of cells comprising a nucleic sequence encoding a tagged hepadnavirus e antigen, like Hepatitis B virus e antigen (HBeAg). Furthermore, the present invention provides nucleic acid sequences encoding a tagged hepadnavirus e antigen and proteins encoded thereby. Also kits for use in the screening methods are provided.

Loading Drexel University collaborators
Loading Drexel University collaborators